Growth Hormone, Placental, Recombinant, Human, 20kD (hGH)

Placental growth hormone, or growth hormone variant (GH-V), is a member of the growth hormone gene family. Its physiologic role during pregnancy remains undefined. Although extensive work has been done characterizing the signaling pathways activated by hGH, the signaling pathways which are activated by GH-V have not been characterized. Human placental GH (hPGH) replaces pituitary GH during pregnancy. hPGH is correlated to serum IGF-I in normal pregnancies and in pregnancies complicated by fetoplacental disorders \n\nRecombinant Placental Human GH-20K is a single, non-glycosylated, polypeptide chain containing 177 amino acids and having a molecular mass of 20498 Dalton. Predicted pI=8.20. PGH-20K-pl is devoid of lactogenic (prolactin receptor mediated) activity characteristic to pituitary GHs. \n\nSequence:\nThe sequence of the first five N-terminal amino acids was determined and was found to be Ala-Phe-Pro-Thr-Ile. \n\nDimers and Aggregates:\n(same/less than) 1% as determined by silver-stained SDS-PAGE gel analysis. \n\nBiological Activity:\nPlacental Growth Hormone-20K is fully biologically active when compared to World Health Organization (WHO) reference standard. \n\nEndotoxin:\n(same/less than) 0.1ng/ug (IEU/ug) of Recombinant Placental Growth Hormone. \n\nProtein Content:\nProtein quantitation was carried out by two independent methods: \n 1. UV spectroscopy at 280 nm using the absorbency value of 1.14 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). \n 2. Analysis by RP-HPLC, using a calibrated solution of Recombinant Placental Growth Hormone-20K as a Reference Standard.\n\nReconstitution:\nReconstitute and dilute the lyophilized Placental-GH in 0.4% NaHCO3 adjusted to pH 11, which can then be further diluted to other aqueous solutions. \n\nStorage and Stability:\nLyophilized powder may be stored at 4 degrees C for short-term only. Reconstitute to nominal volume by adding sterile 0.4% NaHCO3 and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

G9000-18A

Size

100ug

Form

Supplied as a lyophilized powder in 0.0045mM NaHCO3, pH 11.

Purity

(same/more than) 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified.

References

1. Placental growth hormone in Down's syndrome screening. Baviera G, Carbone C, Mastrantonio P, J Matern Fetal Neonatal Med 2004 Oct;16(4):241-3 2. A longitudinal study of intrauterine growth and the placental growth hormone (GH)-insulin-like growth factor I axis in maternal circulation: association between placental GH and fetal growth. Chellakooty M, Vangsgaard K, Scheike T, Main KM, J Clin Endocrinol Metab 2004 Jan;89(1):384-91 3. Placental growth hormone during pregnancy in a growth hormone deficient woman with type 1 diabetes compared to a matching diabetic control group. Fuglsang J, Lauszus F, Ovesen P, Growth Horm IGF Res 2004 Feb;14(1):66-70 4. Human placental growth hormone increases expression of the p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. Barbour LA, Shao J, Leitner W, Endocrinology 2004 Mar;145(3):1144-50 5. Human placental growth hormone, insulin-like growth factor I and -II, and insulin requirements during pregnancy in type 1 diabetes. Fuglsang J, Lauszus F, Ovesen P, J Clin Endocrinol Metab 2003 Oct;88(10):4355-61 6. Human placental growth hormone, insulin-like growth factor I and -II, and insulin requirements during pregnancy in type 1 diabetes. Fuglsang J, Lauszus F, Ovesen P, J Clin Endocrinol Metab 2003 Sep;88(9):4355-61.